第1届
Point-of-Care Testing
-重点照护检验讨论会-
分子诊断的实用化
2月19日～20日

随著开发期间的缩短和经费的节减，提高了临床试验效率化的必要性，为使患者阶层化而利用重点照护检验的情况增加。此讨论会中采用因应重点照护检验诊断的技术和倾向，检讨新药开发领域各种用途之适合性，并表明对诊断服务的服务提供商和制药公司的商机。此外，亦表示引进诊断（companion）的问题和重点照护检验被视为有效工具的理由等。

Who Should Attend: VPs, Directors, Managers, CEOs, CSOs, Professors and Scientists from Large Pharma, Biotechs and Academia working in fields such as Diagnostics, Pathology, Infectious Diseases, R&D, Product Development, and Biotechnology.

Topics will include, but are not limited to:

• Technologies and trends in point-of-care diagnostics
• Deciding which companion diagnostic test to use
• Implementing companion diagnostics
• Partnering with a point-of-care diagnostic developer
• Deciding on criteria for selecting a POC device or provider
• Economics of the POC model for pharma
• Infrastructure needed to make POC work in pharma
• When in the drug development cycle is the right time to bring in a companion diagnostic?
• Who should own the test?
• Who should develop it?
• Can central labs obviate the need for POC in clinical trials?
• Which POC tests are ready for market?

The deadline for submission is July 29, 2011.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.